Venous thrombosis in a systemic lupus erythematosus patient with antiphospholipid antibodies coinciding with mild Covid-19

Helms J Tacquard C Severac F , et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089–1098.

Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and anti-phospholipid antibodies in patients with Covid-19. N Engl J Med 2020; 382: e38.

Cervera R Asherson RA Acevedo ML , et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 2004; 63: 1312–1317.

Serrano R Pons-Estel GJ Espinosa G , et al. Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. Lupus 2020; 29: 1050–1059.

Mendoza-Pinto C García-Carrasco M Cervera R. Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant). Curr Rheumatol Rep 2018; 20: 62.

Pengo V Ruffatti A Legnani C , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118: 4714–4718.

Garcia D Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018; 378: 2010–2021.

Bertin D, Brodovitch A, Beziane A, et al. Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity. Arthritis Rheumatol. Epub ahead of print 21 June 2020. DOI:10.1002/art.41409.

Levi M Hunt BJ. Thrombosis and coagulopathy in COVID-19: an illustrated review. Res Pract Thromb Haemost 2020; 4: 744–751.

Mathian A Mahevas M Rohmer J , et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020; 79: 837–839.